GI Innovation, Inc. (KOSDAQ:358570)
South Korea · Delayed Price · Currency is KRW 18,520
+100 (0.54%)
Nov 20, 2025, 3:30 PM KST
GI Innovation Company Description
GI Innovation, Inc., a bio-venture company, engages in the research and development of protein new drugs.
The company is developing GI-101, an immune anticancer drug with novel dual fusion protein in Phase I/II clinical trial; and GI-301, an IgE-mediated allergy treatment designed as a fusion protein that is in Phase I clinical trial.
It is also developing GI-10N, an immuno-oncology drug; GI-30N, a drug for allergic and fibrotic diseases; and GI-20N, a drug for metabolic diseases.
The company was founded in 2017 and is based in Seoul, South Korea.
GI Innovation, Inc.
| Country | South Korea |
| Founded | 2017 |
| Industry | Biotechnology |
| Sector | Healthcare |
Contact Details
Address: Munjeong Station Terra Tower Seoul, 05855 South Korea | |
| Phone | 82 2 404 2003 |
| Website | gi-innovation.com |
Stock Details
| Ticker Symbol | 358570 |
| Exchange | KOSDAQ |
| Fiscal Year | January - December |
| Reporting Currency | KRW |
| ISIN Number | KR7358570000 |
| SIC Code | 2836 |